The FDA on December 20, 2019 granted accelerated approval to ENHERTU® for patients with unresectable or metastatic HER2-positive breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting. ENHERTU® is a product of Daiichi Sankyo.
Other Pages – Bottom Ad
Advertisement
Subscribe
